Naftidrofuryl

Naftidrofuryl
Clinical data
Trade namesPraxilene, others
Other namesNafronyl; Naftidrofurile; Naftifurine; EU-1806; EU1806; LS-121; LS121
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral[1]
Drug classSerotonin 5-HT2A receptor antagonist; Vasodilator
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability20–78% (in different studies)[1]
Protein binding80%[1]
MetabolismHepatic[1]
Onset of action0.8–1.0 hours (TmaxTooltip time to peak levels)[1]
Elimination half-life1.2–2 hours[1]
Duration of action2–3 hours[1]
Identifiers
  • (RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.045.960
Chemical and physical data
FormulaC24H33NO3
Molar mass383.532 g·mol−1
3D model (JSmol)
  • O=C(OCCN(CC)CC)C(Cc2c1ccccc1ccc2)CC3OCCC3
  • InChI=1S/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3 Y
  • Key:KBAFPSLPKGSANY-UHFFFAOYSA-N Y
  (verify)

Naftidrofuryl, also known as nafronyl and sold under the brand name Praxilene among others, is a serotonin 5-HT2 receptor antagonist which is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders.[1][2][3][4][5] It is taken orally.[1]

Medical uses

Naftidrofuryl is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders.[1][2][5] It is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.[1] Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[6] Naftidrofuryl may be effective for relieving the pain of muscle cramps.[7]

Adverse effects

Naftidrofuryl has been associated with nausea, abdominal pain and rash.[8][1] Rarely, hepatitis and liver failure have been reported.[1][8]

Pharmacology

Pharmacodynamics

Naftidrofuryl acts as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][5][9][10]

Pharmacokinetics

The oral bioavailability of naftidrofuryl is 20 to 78% in different studies.[1] Its time to peak levels is 0.8 to 1.0 hours.[1] There is some evidence that naftidrofuryl crosses the blood–brain barrier and penetrates into the central nervous system.[11][12] The drug's plasma protein binding is 80%.[1] It is metabolized in the liver.[1] The elimination half-life of naftidrofuryl is 1.2 to 2 hours.[1] Its half-life is longer in the elderly than in younger people.[1] The drug's duration of effects is 2 to 3 hours and closely parallels circulating levels of naftidrofuryl.[1]

History

Naftidrofuryl was first described in the scientific literature by at least 1966.[4]

Society and culture

Names

Naftidrofuryl is the generic name of the drug and its (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and JANTooltip Japanese Accepted Name.[2][3][4][5] It is also known as naftidrofurile (DCITTooltip Denominazione Comune Italiana) or as nafronyl (USANTooltip United States Adopted Name.[2][3][4][5] Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl Retard, Stimlor, and Vascuprax, among others.[2][3][4]

Availability

Naftidrofuryl is marketed and used widely throughout the world.[2][3]

See also

References

  1. ^ a b c d e f g h i j k l m n o p q r s t u Barradell LB, Brogden RN (April 1996). "Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease". Drugs & Aging. 8 (4): 299–322. doi:10.2165/00002512-199608040-00005. PMID 8920176.
  2. ^ a b c d e f Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. ISBN 978-3-88763-075-1. Retrieved 17 January 2026.
  3. ^ a b c d e "Naftidrofuryl (International database)". Drugs.com. 6 January 2026. Retrieved 17 January 2026.
  4. ^ a b c d e Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 18 January 2026.
  5. ^ a b c d e Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. ISBN 978-94-011-4439-1. Retrieved 18 January 2026.
  6. ^ "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de. Archived from the original on 2018-09-20. Retrieved 2018-12-13.
  7. ^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology". Neurology. 74 (8): 691–696. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
  8. ^ a b Brayfield A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.
  9. ^ Lanzer P, Topol EJ (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.
  10. ^ Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T (August 2009). "Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. PMID 19672037.
  11. ^ Castleden CM (January 1984). "Therapeutic possibilities in patients with senile dementia". Journal of the Royal College of Physicians of London. 18 (1): 28–31. PMC 5370945. PMID 6323706.
  12. ^ Rico AG, Godfrain JC, Benard P, Braun JP, Fontaine L, Belleville L (1974). "[Study of the metabolism of naftidrofuryl using radioactive carbon. Determination by liquid scintillation after administration to rats. Autoradiography of mice]" [Study of the metabolism of naftidrofuryl using radioactive carbon. Determination by liquid scintillation after administration to rats. Autoradiography of mice]. Therapie (in French). 29 (2): 281–93 passim. PMID 4849813.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.